All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The Lupus Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your Lupus Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The Lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lupus Hub cannot guarantee the accuracy of translated content. The Lupus Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

Visual abstract | Efficacy of belimumab on renal outcomes: post-hoc analyses from phase III BLISS-LN trial

Oct 11, 2023
Learning objective: After reading this article, learners will be able to discuss the efficacy of belimumab on renal outcomes in subgroups of patients with newly diagnosed and relapsed lupus nephritis (LN).

Bookmark this article

Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus, affecting approximately 40% of the patients. Furthermore, around 44% of the patients with class IV LN develop end-stage kidney disease within 15 years. Notably, 13%37% of patients undergoing standard therapy (ST) for LN experience renal flare within 35 years, emphasizing the need for novel treatments to preserve kidney function.

The phase III, randomized, double-blind BLISS-LN study (NCT01639339) has demonstrated that the addition of belimumab to ST improves renal outcomes in patients with active LN. However, data on its efficacy at different disease stages or with different induction regimens is limited. Here, we present a visual abstract summarizing post-hoc analyses from the BLISS-LN trial in patients with newly diagnosed or relapsed LN, including those with or without glucocorticoid pulses at induction.1

Visual Abstract

To download this visual abstract, click below.

Download here


Subscribe to get the best content related to lupus delivered to your inbox